CR20220016A - DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS - Google Patents

DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS

Info

Publication number
CR20220016A
CR20220016A CR20220016A CR20220016A CR20220016A CR 20220016 A CR20220016 A CR 20220016A CR 20220016 A CR20220016 A CR 20220016A CR 20220016 A CR20220016 A CR 20220016A CR 20220016 A CR20220016 A CR 20220016A
Authority
CR
Costa Rica
Prior art keywords
pyrido
dihydro
bcl
pro
treating cancer
Prior art date
Application number
CR20220016A
Other languages
English (en)
Inventor
András Herner
Maïa Chanrion
Emma Sanders
James Brooke Murray
Frédéric Colland
Paul Webb
Attila Paczal
James Edward Paul Davidson
Ana Leticia Maragno
Mátyás Pál Timári
Jérôme-Benoît Starck
Simon Bedford
Tibor Novák
Mark Philip Dodsworth
András Kotschy
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of CR20220016A publication Critical patent/CR20220016A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de fórmula (I): en donde Het, Het1, Het2, A4, A5, Z1, R1, R2 y R3 son como se definen en la descripción.
CR20220016A 2019-07-29 2020-07-28 DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS CR20220016A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19188749 2019-07-29
PCT/EP2020/071181 WO2021018858A1 (en) 2019-07-29 2020-07-28 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer

Publications (1)

Publication Number Publication Date
CR20220016A true CR20220016A (es) 2022-03-02

Family

ID=67514283

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220016A CR20220016A (es) 2019-07-29 2020-07-28 DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS

Country Status (29)

Country Link
US (1) US20220363677A1 (es)
EP (1) EP4003989B1 (es)
JP (1) JP2022542595A (es)
KR (1) KR20220041132A (es)
CN (1) CN114450284B (es)
AR (1) AR119494A1 (es)
AU (1) AU2020319652A1 (es)
BR (1) BR112022001373A2 (es)
CA (1) CA3148506A1 (es)
CL (1) CL2022000102A1 (es)
CO (1) CO2022000612A2 (es)
CR (1) CR20220016A (es)
DK (1) DK4003989T3 (es)
FI (1) FI4003989T3 (es)
GE (1) GEP20237581B (es)
HR (1) HRP20240392T1 (es)
IL (1) IL289933A (es)
JO (1) JOP20220010A1 (es)
LT (1) LT4003989T (es)
MA (1) MA56649B1 (es)
MX (1) MX2022001191A (es)
PE (1) PE20220705A1 (es)
PL (1) PL4003989T3 (es)
PT (1) PT4003989T (es)
RS (1) RS65248B1 (es)
SI (1) SI4003989T1 (es)
TW (1) TWI751629B (es)
UY (1) UY38810A (es)
WO (1) WO2021018858A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018336171B2 (en) 2017-09-22 2023-01-05 Jubilant Epipad LLC Heterocyclic compounds as PAD inhibitors
CA3076476A1 (en) 2017-10-18 2019-04-25 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
WO2019087214A1 (en) 2017-11-06 2019-05-09 Jubilant Biosys Limited Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
KR20200092346A (ko) 2017-11-24 2020-08-03 주빌런트 에피스크라이브 엘엘씨 Prmt5 억제제로서의 헤테로사이클릭 화합물
JP7279063B6 (ja) 2018-03-13 2024-02-15 ジュビラント プローデル エルエルシー Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物
EP4251209A1 (en) * 2020-11-24 2023-10-04 Novartis AG Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
KR20230170644A (ko) * 2021-02-02 2023-12-19 르 라보레또레 쎄르비에르 선택적 bcl-xl protac 화합물 및 사용 방법
CN114181039A (zh) * 2021-12-23 2022-03-15 凯美克(上海)医药科技有限公司 一种4,4-二苯基-3-丁烯-1-醇的合成方法
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
TW202404645A (zh) 2022-05-20 2024-02-01 瑞士商諾華公司 Met bcl-xl抑制劑抗體-藥物結合物及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5770102B2 (ja) * 2008-12-19 2015-08-26 ジェネンテック， インコーポレイテッド 複素環化合物と使用方法
CN103987711B (zh) * 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
TW201414737A (zh) * 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3468615A1 (en) * 2016-06-08 2019-04-17 AbbVie Inc. Anti-egfr antibody drug conjugates
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
CO2022000612A2 (es) 2022-01-28
JP2022542595A (ja) 2022-10-05
CN114450284A (zh) 2022-05-06
KR20220041132A (ko) 2022-03-31
MX2022001191A (es) 2022-02-22
AR119494A1 (es) 2021-12-22
CL2022000102A1 (es) 2022-11-04
TW202118764A (zh) 2021-05-16
LT4003989T (lt) 2024-02-12
AU2020319652A1 (en) 2022-02-10
EP4003989B1 (en) 2023-12-27
MA56649B1 (fr) 2024-02-29
PT4003989T (pt) 2024-01-30
US20220363677A1 (en) 2022-11-17
BR112022001373A2 (pt) 2022-06-07
PL4003989T3 (pl) 2024-04-29
PE20220705A1 (es) 2022-05-04
FI4003989T3 (fi) 2024-03-21
WO2021018858A1 (en) 2021-02-04
SI4003989T1 (sl) 2024-04-30
RS65248B1 (sr) 2024-03-29
DK4003989T3 (da) 2024-03-25
CA3148506A1 (en) 2021-02-04
GEP20237581B (en) 2023-12-25
TWI751629B (zh) 2022-01-01
HRP20240392T1 (hr) 2024-06-07
IL289933A (en) 2022-03-01
JOP20220010A1 (ar) 2023-01-30
UY38810A (es) 2021-02-26
EP4003989A1 (en) 2022-06-01
CN114450284B (zh) 2024-05-07

Similar Documents

Publication Publication Date Title
CR20220016A (es) DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
US9975907B2 (en) Pyrimidinones as PI3K inhibitors
AU2015266492B2 (en) Certain protein kinase inhibitors
CA2647391C (en) Kinase antagonists
AU2013315387B2 (en) Amino-quinolines as kinase inhibitors
PH12021551117A1 (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
AR049769A1 (es) Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
BRPI0719333A2 (pt) Midazotriazinas e imidazopirimidinas como inbidores de cinase
CA2783727A1 (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
US20210346395A1 (en) Inhibitors of egfr and methods of use thereof
TW200738243A (en) Novel process and formulations
WO2017133701A1 (en) Certain protein kinase inhibitors
JP2021501208A (ja) 急性骨髄性白血病又は転移性乳癌の予防又は治療用薬剤学的組成物
Sunose et al. Discovery of 5-(2-amino-[1, 2, 4] triazolo [1, 5-a] pyridin-7-yl)-N-(tert-butyl) pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
KR20230009367A (ko) 헌팅턴병 치료 화합물
AU2017280412B2 (en) Substituted pyrrolo (2, 3-D) pyridazin-4-ones and pyrazolo (3, 4-D) pyridazin-4-ones as protein kinase inhibitors
US20190308963A1 (en) Heterocyclic compounds and uses thereof
EP3287436B1 (en) Compounds and compositions for use in the treatment of bcat1-mediated diseases
JPS58116488A (ja) セフアロスポリン誘導体、その製法及びこの化合物を含む抗菌作用を有する医薬組成物